Peachtree Bioresearch Solutions
Private Company
Funding information not available
Overview
Peachtree BioResearch Solutions, founded in 2009, is a specialized clinical CRO that has recently undergone a transformative merger with Netherlands-based Julius Clinical. This strategic combination creates a global, full-service CRO with deep expertise in CNS, cardio-metabolic, renal, and rare diseases, significantly expanding its operational footprint across North America and Europe. The merged entity leverages nearly a decade of prior collaboration to offer sponsors a blend of scientific excellence, global reach, and a personalized, flexible service model. Supported by private equity from Ampersand Capital Partners, the new organization is positioned to address the increasing complexity of international clinical development.
Technology Platform
Integrated suite of clinical trial services (feasibility, monitoring, data management, biostatistics, etc.) and a global operational network focused on a solutions-based approach for clinical development.
Opportunities
Risk Factors
Competitive Landscape
The company competes in the highly fragmented global CRO market, facing competition from large, full-service CROs (e.g., IQVIA, Labcorp, Parexel) and numerous smaller, niche providers. Its post-merger strategy is to differentiate through deep therapeutic expertise in CNS and rare diseases, global capabilities, and a flexible service model tailored for small and mid-size sponsors.